# CALYPSO (NCT02819596)

> MEDI4736 Combinations in Metastatic Renal Cell Carcinoma

No report yet. It can be ordered.

- Drugs tested: savolitinib plus durvalumab; durvalumab plus tremelimumab; savolitinib
- Indication: metastatic clear cell and papillary renal cell carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02819596
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Queen Mary University of London
- Conditions: Renal Clear Cell Carcinoma; Renal Papillary Cell Carcinoma
- Interventions: Savolitinib; MEDI4736; Tremelimumab
- Enrollment: 69
- Primary outcome: Identify Dose Limiting Toxicity -Phase Ib
- Primary outcome: Overall response (OR) in patients with metastatic clear cell renal cancer
- Primary outcome: Overall response (OR) in patients with metastatic Papillary cell renal cancer
- Primary outcome: Overall response (OR)in patients with metastatic renal cell cancer -Biomarker enrichment phase

## Questions raised in the commentary

_Automated from the 40 newest of 48 indexed sources (Feb 2023 – Oct 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice._

- Whether MET status identifies patients who benefit from savolitinib plus durvalumab
- Whether ctDNA can serve as a clinically useful prognostic biomarker in papillary disease
- Whether PD-L1 or other biomarkers can guide treatment selection

Also discussed: papillary RCC treatment landscape.

## Indexed commentary on CALYPSO so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 28
- YouTube: 13
- Podcasts: 7

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=calypso-nct02819596

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02819596", "email": "<work email>"}; the inbox owner confirms by the emailed link.